N/A
Manufactured by ViiV Healthcare Company
28,565 FDA adverse event reports analyzed
Last updated: 2026-04-14
DOLUTEGRAVIR SODIUM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by ViiV Healthcare Company. The most commonly reported adverse reactions for DOLUTEGRAVIR SODIUM include PAIN, ANXIETY, EMOTIONAL DISTRESS, ANHEDONIA, CHRONIC KIDNEY DISEASE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DOLUTEGRAVIR SODIUM.
Out of 8,753 classified reports for DOLUTEGRAVIR SODIUM:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 28,565 FDA FAERS reports that mention DOLUTEGRAVIR SODIUM. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include PAIN, ANXIETY, EMOTIONAL DISTRESS, ANHEDONIA, CHRONIC KIDNEY DISEASE, FATIGUE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list ViiV Healthcare Company in connection with DOLUTEGRAVIR SODIUM. Always verify the specific product and NDC with your pharmacist.